The anti-PD1 antibody nivolumab only demonstrated survival benefit in advanced melanoma patients without the BRAF V600 mutation, with a 72.9% survival rate at 1 year and increase in median progression-free survival by nearly 3 months as a second-line therapy in patients that progressed after receiving ipilimumab and/or BRAF inhibitor therapy [46]. This evidence concerns the gene PDCD1 and melanoma.